Document ID: chunk:federal_register_of_legislation:F2025C00036:front:0:p4
Version: federal_register_of_legislation:F2025C00036
Segment Type: other
Provision Reference: 
Character Range: 8800–12200

medicine as orphan drug
16K Period during which designation is in force
16L Extension of designation
16M Revocation of designation
Part 3C—Therapeutic goods (priority applicant) determinations
16P Application of Part
16Q Application for therapeutic goods (priority applicant) determination
16R Making of therapeutic goods (priority applicant) determination
16S Period during which therapeutic goods (priority applicant) determination is in force
16T Revocation of therapeutic goods (priority applicant) determination
Part 3D—Biologicals (priority applicant) determinations
16U Application of Part
16V Application for biologicals (priority applicant) determination
16W Making of biologicals (priority applicant) determination
16X Period during which biologicals (priority applicant) determination is in force
16Y Revocation of biologicals (priority applicant) determination
Part 4—Licensing of manufacturers
17 Exempt goods for the purposes of subsection 34(1) of the Act
18 Exempt Persons
19 Requirements for licence holders
20 Conditions of licences
21 Persons having control of production etc to be named
22 Transfer of licences
Part 5—Examination, testing and analysis of goods
23 Interpretation
24 Authorised officer—powers and duties
25 Appointment of analysts and official analysts and powers of official analysts
26 Taking of samples for testing
26A Receiving samples for testing
27 Examination and testing of sample
28 Tests for determining conformity with a standard or compliance with essential principles
29 Certificate of responsible analyst
30 Review of results of examination and analysis
31 Payment for samples
32 Offences relating to analysis etc
33 Production of identity card
Part 5A—Exceptional release
33A Prescribed circumstances under which biologicals may be imported, exported or supplied
33B Conditions for supply of biologicals
33C Report on release of nonconforming biological
Part 6—Committees
Division 1A—Advisory Committee on Medicines
35 Establishment
35A Functions
35B Membership
Division 1D—Advisory Committee on Medical Devices
38 Establishment
38A Functions
38B Membership
Division 1E—Advisory Committee on Complementary Medicines
39 Establishment
39A Functions
39B Membership
Division 1EA—Advisory Committee on Biologicals
39C Establishment
39D Functions
39E Membership
Division 1EB—Advisory Committee on Vaccines
39F Establishment
39G Functions
39H Membership
Division 1F—General
40 Application of this Division
41 Appointment of members
41A Appointment of the chair
41B Resignation or vacancy
41C Termination of appointment
41D Leave of absence
41E Acting members
41F Committee procedures
41G Meetings
41H Presiding member
41I Quorum
41J Voting
42 Miscellaneous
Division 3A—Advisory Committee on Medicines Scheduling
Subdivision 3A.1—Preliminary
42ZCA Definitions for Division 3A
Subdivision 3A.2—Constitution of Committee
42ZCB Membership of Committee
42ZCC Committee members
42ZCD Appointed members
42ZCE Nominated members
42ZCF Appointment of the Chair and acting Chair
42ZCG Resignation or vacancy
42ZCH Termination of appointment
42ZCI Leave of absence
42ZCJ Acting members
Subdivision 3A.3—Committee meetings
42ZCK Committee meetings
42ZCL Meeting procedure
42ZCM Presiding member
42ZCN Quorum
42ZCO Voting
42ZCP Miscellaneous
Division 3B—Advisory Committee on Chemicals Scheduling
Subdivision 3B.1—Preliminary
42ZCQ Definitions for Division 3B
Subdivision